Literature DB >> 16257154

Formulation design of a novel fast-disintegrating tablet.

Takao Mizumoto1, Yoshinori Masuda, Takeshi Yamamoto, Estuo Yonemochi, Katsuhide Terada.   

Abstract

As our society is becoming increasingly aged, the development of an appropriate dosage form for the elderly patients is mostly desirable. A novel fast-disintegrating tablet was investigated in this study as a user-friendly dosage form for the aged. Advantages of this formulation have sufficient hardness and can be manufactured by commonly used equipment. Saccharides can be divided into high- and low-compressibility categories, and an appropriate material for fast-disintegrating tablets was created by taking advantage of this fact. To improve the compressibility of low-compressibility saccharides, particle modification was conducted by coating and granulating a low-compressibility saccharide with a high one to enable the production of a fast-disintegrating tablet. Another discovery was that the high-compressibility saccharide used as a binder solution was present in an amorphous state after the granulation process. The crystal change from amorphous to crystal state intentionally by a conditioning process after compression enabled to increase tablet hardness by strengthening adhesion between particles. The conditioning process made it possible to achieve sufficient hardness while maintaining the fast disintegration time. As a result, this fast-disintegrating tablet that can be manufactured by commonly used equipment, can be used for the dosing of a wide range drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16257154     DOI: 10.1016/j.ijpharm.2005.09.009

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Maltodextrin: a novel excipient used in sugar-based orally disintegrating tablets and phase transition process.

Authors:  Yosra Shaaban R Elnaggar; Magda A El-Massik; Ossama Y Abdallah; Abd Elazim R Ebian
Journal:  AAPS PharmSciTech       Date:  2010-04-20       Impact factor: 3.246

2.  Development of taste masked oral formulation of ornidazole.

Authors:  V R Kapoor
Journal:  Indian J Pharm Sci       Date:  2010-03       Impact factor: 0.975

3.  Nano and Microparticulate Chitosan Based System for Formulation of Carvedilol Rapid Melt Tablet.

Authors:  Ravindra Patil; Vishal Pande; Raju Sonawane
Journal:  Adv Pharm Bull       Date:  2015-06-01

4.  A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets.

Authors:  Feng-Qian Li; Cheng Yan; Juan Bi; Wei-Lin Lv; Rui-Rui Ji; Xu Chen; Jia-Can Su; Jin-Hong Hu
Journal:  Int J Nanomedicine       Date:  2011-04-28

5.  Formulation and evaluation of a novel matrix-type orally disintegrating Ibuprofen tablet.

Authors:  Hoda Tayebi; Seyed Alireza Mortazavi
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

6.  The role of SeDeM for characterizing the active substance and polyvinyilpyrrolidone eliminating metastable forms in an oral lyophilizate-A preformulation study.

Authors:  Paloma Flórez Borges; Encarna García-Montoya; Pilar Pérez-Lozano; Enric Jo; Montserrat Miñarro; Albert Manich; Josep Maria Suñé-Negre
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

7.  Study of Orally Disintegrating Tablets Using Erythritol as an Excipient Produced by Moisture-Activated Dry Granulation (MADG).

Authors:  Mizuki Yamada; Agata Ishikawa; Shun Muramatsu; Takayuki Furuishi; Yoshinori Onuki; Kaori Fukuzawa; Etsuo Yonemochi
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-15

8.  Development of fast dispersible aceclofenac tablets: effect of functionality of superdisintegrants.

Authors:  C Mallikarjuna Setty; D V K Prasad; V R M Gupta; B Sa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

9.  Formulation and evaluation of carvedilol melt-in-mouth tablet using mucoadhesive polymer and PEG-6-stearate as hydrophilic waxy binder.

Authors:  Amish Ashvinkumar Dangi; Prakash Bhikhabhai Zalodiya
Journal:  Int J Pharm Investig       Date:  2012-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.